Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dienogest for painful symptoms associated with adenomyosis
ChiCTR2600132541Phase 3Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in adenomyosis comparing Placebo group with Dienogest group (2 arms). Primary endpoint: Change from baseline in maximum VAS score for adenomyosis-related pain at Week 16. Started May 2023; status: completed.
02
Drugs
dienogest
03
Conditions
adenomyosis
Beyond the preview
Go deeper on ChiCTR2600132541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132541.